In the BioHarmony Drug Report Database
Selegiline
Emsam (selegiline) is a small molecule pharmaceutical. Selegiline was first approved as Emsam on 2006-02-27. It is used to treat alzheimer disease, attention deficit disorder with hyperactivity, depressive disorder, parkinson disease, and schizophrenia in the USA. The pharmaceutical is active against amine oxidase [flavin-containing] B. In addition, it is known to target amine oxidase [flavin-containing] A.
Trade Name
|
Emsam |
|---|---|
Common Name
|
selegiline |
ChEMBL ID
|
CHEMBL972 |
Indication
|
alzheimer disease, attention deficit disorder with hyperactivity, depressive disorder, parkinson disease, schizophrenia |
Drug Class
|
Mao inhibitors, type B |
Image (chem structure or protein)